News & Videos - REGENCELL BIOSCIENCE HLD.

You are currently viewing all stock exchange news of the financial instrument REGENCELL BIOSCIENCE HLD. regarding all markets in all languages.

> News Business Wire published a news.

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period • • Business Wire • Stocks

Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022 – 31 March 2022 (EARTH-B Trial) 1 October 2021 – 31 January 2022 (EARTH-A Trial) 1 October 2021 – 31 March 2022 (EARTH-A and EARTH-B Trials, combined) Number of patients 51 37 88 Complete symptoms elimination in 6 days (% of patients) 94.1 97.3 95.5 Elimination of one or more symptoms after 1 full dose of RGC-COV19 TM (% of patients) 90.2 83.8 87.5...

Thank you Chart

> News Business Wire published a news.

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO • • Business Wire • Stocks

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine (“TCM”) for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system, announced that Yat-Gai Au, the Company’s Chairman and CEO, made purchases of ordinary shares in Regencell (“Ordinary Shares”)...

Thank you Chart

> News ACCESSWIRE published a news.

Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network • • ACCESSWIRE • Stocks

LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings Limited (NASDAQ:RGC), including: Jay Lee, CEO of Regencell Bioscience Asia Limited, and Paul Niewiadomski, Independent Director. Regencell is an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and...

Thank you Chart

> News Business Wire published a news.

La formule liquide expérimentale RGC-COV19 TM de Regencell Bioscience a démontré son efficacité, chez ses patients recrutés, dans l'élimination des symptômes légers à modérés de la COVID-19 au cours d'une période de traitement de 6 jours, dans le cadre de son essai d'efficacité EARTH Regencell Bioscience Holdings Limited (NASDAQ: RGC) (" Regencell " ou la " Société ") a annoncé aujourd'hui les résultats d'une analyse d'un total de 37 personnes recrutées dans le cadre de son...

Thank you Chart

> News Business Wire published a news.

Ensayo de eficacia EARTH: la fórmula líquida en investigación RGC-COV19TM de Regencell Bioscience demuestra eficacia en los pacientes inscritos al eliminar los síntomas leves o moderados de la COVID-19 en un período de tratamiento de seis días • • Business Wire • Stocks

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (« Regencell » o la « Compañía ») acaba de publicar los resultados del análisis de un grupo de 37 personas inscritas en el ensayo de eficacia denominado E valuation and A ssessment of RGC-COV19 TM T CM through a H olistic approach (« EARTH »), llevado a cabo por Regencell Bioscience Asia Limited (« Regencell Asia ») con su producto candidato de medicina china tradicional (en adelante MCT) RGC-COV19 TM [Regencell Bioscience...

Thank you Chart

> News Business Wire published a news.

Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial • • Business Wire • Stocks

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“ Regencell ” or the “ Company ”) today announced the results from an analysis of a total of 37 individuals enrolled in its E valuation and A ssessment of RGC-COV19 TM T CM through a H olistic approach (“ EARTH ”) efficacy trial conducted by Regencell Bioscience Asia Limited (“ Regencell Asia ”) of its novel COVID-19 oral TCM candidate RGC-COV19 TM (Regencell Bioscience (RGCA-CV01) liquid formulation). The results have yet to...

Thank you Chart